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Stable nucleic acid lipid vesicles (SNALPs) encapsulating miR-34a to treat multiple myeloma (MM) were developed. Wild type or
completely 2󸀠-O-methylated (OMet) MiR-34a was used in this study. Moreover, SNALPs were conjugated with transferrin (Tf) in
order to target MM cells overexpressing transferrin receptors (TfRs). The type of miR-34a chemical backbone did not significantly
affect the characteristics of SNALPs in terms of mean size, polydispersity index, and zeta potential, while the encapsulation of
an OMet miR-34a resulted in a significant increase of miRNA encapsulation into the SNALPs. On the other hand, the chemical
conjugation of SNALPs with Tf resulted in a significant decrease of the zeta potential, while size characteristics and miR-34a
encapsulation into SNALPs were not significantly affected. In an experimental model of MM, all the animals treated with SNALPs
encapsulating miR-34a showed a significant inhibition of the tumor growth. However, the use of SNALPs conjugated with Tf and
encapsulating OMet miR-34a resulted in the highest increase of mice survival. These results may represent the proof of concept for
the use of SNALPs encapsulating miR-34a for the treatment of MM.
1. Introduction
MicroRNAs (miRNAs) are noncoding nucleic acids able to
regulate basic biological functions and pathways essential to
tumor development and progression [1]. In the last years, the
development of miRNA-based anticancer therapies received
growing attention. Some miRNAs, such as miR-34a, have a
tumor suppressor activity and their reintroduction into dis-
eased tissues can drive a therapeutic response [2]. The devel-
opment of therapies based on miRNAs, as well as in general
on nucleic acids, is hampered by several drawbacks, including
cost and production of clinical grade material [3], degrada-
tion and inactivation by nucleases in plasma and cells [4],
poor intracellular delivery [5, 6], rapid plasma elimination
[7–9], and renal and dose-limiting hemodynamic toxicities
[10]. For antisense oligonucleotides (ONs), which are furthest
along the clinical development, nuclease sensitivity has been
minimized through chemical modifications to the nucleic
acid backbones and/or sugars [11], while hemodynamic
toxicities have been reduced through the use of repeated,
slow infusions (2 h) or continual infusion protocols up to 21
days [12]. The use of nanovectors for the delivery of nucleic
acids represents a valid and widely investigated approach to
overcome the previously described biopharmaceutical issues
[11, 13]. This will be particularly critical for RNA agents on
whichmodificationswould be increasinglymore complicated
and costly. Conventional and cationic liposomes have been
used extensively to increase the therapeutic index of a variety
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of ONs by changing their pharmacokinetic and pharma-
codynamic characteristics [14–16]. However, the low ONs
encapsulation efficiency (especially for neutral liposomes),
the instability in serum, and the toxicity issues associated
with the use of cationic lipid [13] limited the in vivo use of
cationic liposomes. The use of an ionizable aminolipid into
the lipid vesicles allowed facilitating the encapsulation of
nucleic acids into the vesicle that can subsequently be brought
at physiological pH with consequent increased stability in
serum [17]. These nanocarriers, the so-called stable nucleic
acid lipid vesicles (SNALPs), have shown promising results
to deliver plasmids, antisense oligonucleotides, and small
interfering RNAs (siRNA) in vivo [18–20].
Previously, our group developed SNALPs encapsulating
miR-34a for the treatment of medulloblastoma cells [21]. The
miR-34 is a family of noncoding RNAs directly regulated
by the transcription factor p53 [22–24]. miR-34a activates
the p53 oncosuppressor activity, by inhibiting cell growth,
inducing apoptosis, and causing a senescence-like phenotype
[25]. Several studies have confirmed that themiR-34 family is
required for normal cell responses to DNA damage following
irradiation in vivo.
Multiplemyeloma is a hematologicmalignancy, incurable
in most cases, which needs development of novel therapeutic
strategies [26]. Deregulated expression of miR-34a in MM
patients had been evidenced [27], thus suggesting an interest
for these molecules as antitumor therapeutic agents. In this
light, a recent report by our group has demonstrated that
miR-34a replacement strategies are active in controlling the
proliferation of several MM cell lines in different animal
models [28]. However, the optimization of the delivery of
miR-34a is required in order to translate these models in the
clinical setting.
The aim of this study was to develop SNALPs encapsu-
lating miR-34a with enhanced delivery properties for MM.
In particular, we investigated the possibility to encapsulate
synthetic miRNAs, namely, wild type miR-34a and a com-
pletely 2󸀠-O-methylated (OMet) miR-34a, into the SNALPs.
Moreover, SNALPs encapsulating miR-34a were conjugated
with transferrin (Tf), in order to achieve improved transfec-
tion efficiency and targeting types of tumor cells. Antitumor
properties of the different miR-34a, encapsulated in SNALPs
or Tf-conjugated SNALPs (Tf-SNALPs), were investigated in
preclinical experimental model of MM.
2. Materials and Methods
1,2-Dioleyl-3-dimethylammonium propane (DODAP) and
N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene
glycol)2000]} (PEG
2000
-Cer
16
) were purchased from Avanti
Polar Lipids. Distearoylphosphatidylcholine (DSPC) was
kindly offered from Lipoid GmbH (Cam, Switzerland). Cho-
lesterol (CHOL), human transferrin (Tf), sodium chloride,
sodium phosphate, HEPES, citric acid, and sodium citrate
were purchased from Sigma Aldrich (USA). Ethanol and
other solvents were obtained from Carlo Erba Reagenti
(Italy). MiR-34a wild type sequence obtained by miR.org
database (5󸀠-UGG CAG UGU CUU AGC UGG UUG U-3󸀠)
was directly synthesized by MWG (Germany). As control
an oligonucleotide with scrambled sequence (miR-NC) was
used (Life Technologies).
2.1. 2󸀠-OMet Oligonucleotide Synthesis and Purification. The
2󸀠-OMet Oligonucleotide were synthesized on a Millipore
CyclonePlusDNAsynthesizer at 1𝜇mol scale, using commer-
cially available 5󸀠-O-(4,4󸀠-dimethoxytrityl)-2󸀠-O-methyl-3󸀠-
O-(2-cyanoethyl-N,N-diisopropyl) RNA phosphoramidite
monomers and 2󸀠-OMet RNA SynBase CPG 1000/110 as
solid phase support (Link technologies). The oligomers were
detached from the support and deprotected by treatment
with concentrated aqueous ammonia at 55∘C for 12 h. The
combined filtrates and washings were concentrated under
reduced pressure, redissolved in H
2
O, analysed, and puri-
fied by anion-exchange high-performance liquid chromatog-
raphy (HPLC) on a Nucleogel SAX column (Macherey-
Nagel, 1000-8/46), using buffer A: 20mM KH
2
PO
4
/K
2
HPO
4
aqueous solution (pH 7.0), containing 20% (v/v) CH
3
CN,
and buffer B: 1M KCl, 20mM KH
2
PO
4
/K
2
HPO
4
aqueous
solution (pH 7.0), containing 20% (v/v) CH
3
CN; a linear
gradient from 0 to 100% B for 45min and flow rate 1mL/min
were used. The purified oligomers were successively desalted
by Sep-Pak C-18 cartridges (Waters) and characterized by ESI
mass spectrometry.
2.2. Preparation of miR-34a Encapsulating SNALPs Con-
jugated or Not with Tf. SNALPs formulations were prepared
by modified ethanol injection method. Briefly, lipid stock
solutions were prepared in ethanol. Aliquots (0.4mL
total volume) of stock lipids (CHOL/DSPC/DODAP/
PEG
2000
-Cer
16
or CHOL/DSPC/DODAP/DSPE-PEG
2000
-
Mal/PEG
2000
-Cer
16
) were added to a glass tube. In a
separated tube, 0.2mg of miRNA was dissolved in 0.6mL of
20mM citric acid at pH 4.0. The two solutions were warmed
for 2-3min to 65∘C and the lipid solution was quickly
added to the miRNA solution under stirring. The mixture
was passed 5 times through 200 nm and 20 times through
100 nm polycarbonate filters using a thermobarrel extruder
(Northern Lipids Inc., Vancouver, BC, Canada) maintained
at approximately 65∘C. Therefore, the preparation was
dialyzed (3,5 kDa cutoff) against 20mM citrate buffer at
pH 4.0 for approximately 1 h to remove excess of ethanol,
followed by further dialysis against HBS (20mM HEPES,
145mM NaCl, and pH 7.4) for 12–18 h to remove the citrate
buffer and to neutralize the DODAP. Unencapsulated
miRNA was removed by DEAE-Sepharose CL-6B column
chromatography. A typical 1mL formulation consisted of
DSPC/CHOL/DODAP/PEG
2000
-Cer
16
or DSPC/CHOL/
DODAP/DSPE-PEG
2000
-Mal/PEG
2000
-Cer
16
(25/45/20/10
or 25/45/20/5/5mol/mol/mol/mol, resp.) and 0.2mg of miR
in a final solution. Tf was coupled on the preformed
SNALPs vesicles containing DSPE-PEG-Mal in the lipid
mix (SNALPs-Mal). Briefly, Tf was thiolated using 2-
iminothiolane (Traut’s reagent). Tf was dissolved in 0.1M
Na-borate buffer/0.1mM EDTA, pH 8, followed by the
addition of Traut’s reagent (1 : 40mol/mol). After incubation
for 60min at room temperature, thiolatedTfwas immediately
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used for conjugation with SNALPs-Mal overnight at room
temperature. The excess of Tf was removed by molecular
exclusion chromatography, Sepharose CL-B4 column.
2.3. SNALPs Characterization: Mean Diameter, Polydispersity
Index, and Zeta Potential. The mean diameter and size dis-
tribution of SNALPs were determined at 20∘C by photon cor-
relation spectroscopy (PCS) (N5, Beckman Coulter, Miami,
USA). Each samplewas diluted in deionized/filtered (0.22 𝜇m
pore size, polycarbonate filters, MF-Millipore, Microglass
Heim, Italy) water and analysed with detector at 90∘ angle.
As measure of the particle size distribution, polydispersity
index (PI) was used. For each batch, mean diameter and
size distribution were the mean of three measures. For each
formulation, the mean diameter and PI were calculated as
the mean of three different batches. The zeta potential (ZP)
of the SNALPs was determined in distilled water at 20∘C
by Zetasizer Nano Z (Malvern, UK). For each batch, mean
diameter, size distribution, and ZP were the mean of three
measures.
2.4. miR-34a Encapsulation into SNALPs Formulations. The
amount of miRNA encapsulated into the SNALPs was
measured spectrophotometrically. Briefly, 10 𝜇L of SNALPs
suspensionwas dissolved in 990 𝜇L ofmethanol and analysed
at 260 nm. Actual loading was calculated as amount (mg) of
miRNA/mg of mg total lipids. The amount of miRNA loaded
into the nanocarriers was expressed asmiRNA actual loading
and encapsulation efficiency, calculated as mg of miRNA/mg
of total lipids and percent ratio between miR actually loaded
into SNALPs and miR theoretical loading, respectively. For
each batch, the results were the mean of three measures. For
each formulation, the results were calculated as the mean
of the measures obtained in three different batches (𝑛 =
3). The phospholipid content of the carrier suspension was
determined by the Stewart assay [29]. Briefly, an aliquot of
the SNALPs suspension was added to a two-phase system,
consisting of an aqueous ammonium ferrothiocyanate solu-
tion (0.1 N) and chloroform.The concentration of DSPC was
obtained by measuring the absorbance at 485 nm into the
organic layer.The concentration of the total lipid content was
calculated considering a constant ratio between the lipids.
2.5. Animals and In Vivo Models of Human MM. Male
CB-17 severe combined immunodeficient (SCID) mice (6-
to 8-week old; Harlan Laboratories, Inc., Indianapolis) were
housed and monitored in our Animal Research Facility. All
experimental procedures and protocols had been approved
by the Institutional Ethical Committee (Magna Graecia
University) and conducted according to protocols approved
by the National Directorate of Veterinary Services (Italy). In
accordance with institutional guidelines, mice were sacrificed
when their tumors reached 2 cm in diameter or in the event
of paralysis or major compromise in their quality of life, to
prevent unnecessary suffering. For our study 25 SCID mice
were inoculated in the interscapular area (sc)with 5× 106MM
cells in 100𝜇L RPMI-1640 medium. After detection of pal-
pable tumors, approximately 3 weeks following injection of
MM cells, animals were randomized into 5 groups including
5 mice per group, and treatments were initiated. Each animal
received a dose of 20 𝜇g ofmiR-34a SNALPs formulation.The
treatment schedule included 5 treatments, three days apart,
via tail vein. The tumor sizes were measured every two days
until the day of first mouse sacrifice, using a caliper, and
volume was calculated using the formula 𝑉 = 0.5 × 𝑎 × 𝑏2,
where 𝑎 and 𝑏 are the long and short diameters of the tumor,
respectively.
2.6. Survival Analysis and Kaplan-Meier Plot. Survival was
evaluated from the first day of treatment until death or
sacrifice of animals. The observations were followed until
last animal death or the tumors reached 2 cm in diameter
according to our institutional guidelines. Percent of mice that
survive with respect to the totality of animals included in
each group is calculated and used to plot the survival curves
(Kaplan-Meier curve).
2.7. FACS Analysis of TfR Expression in SKMM-1 Multiple
Myeloma Cells. For determination of cell surface expression
of TfR, fluorescence-activated cell sorting (FACS) analysis
was performed using indirect staining of TfR (CD71). Briefly,
we have seeded 50,000 SKMM-1 cells/well in 6 multiwell
plates and incubated at 37∘C for 24, 48, and 72 h. At the
established times, the cells were collected, counted in aBurker
chamber, and centrifuged at 1,300 rpm for 5min at 4∘C in
order to remove the medium. The cells were suspended
in PBS in order to obtain 500,000 cells for each time
point. After another centrifugation at 2,000 rpm at 4∘C for
5min, the cells were suspended in 4% paraformaldehyde and
incubated for 15min at 4∘C in the dark. Thereafter, after
another centrifugation the cells were suspended in PBS/BSA
(1%w/v) and incubated for 10min at 4∘C.Thereafter, the cells
were incubated with a primary mouse monoclonal antibody
raised against human TfR (CD71, H68.4, dilution: 1 : 100;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) or with an
irrelevant immunoglobulin (IgG1) or in PBS overnight at 4∘C.
After incubation with primary antibody, the cells were again
centrifuged and incubatedwith the secondary antibody (anti-
mouse-FITC), in the dark for 1 h at 4∘C. After washing, FACS
sorting was performed using a FACScan (Becton Dickinson,
MountainView, CA,USA), and analysis was performed using
CellQuest 2.0 (Becton Dickinson).
2.8. Statistical Analysis. Student’s 𝑡-test, two-tailed test, and
Log rank test were used to calculate all reported 𝑃 val-
ues using GraphPad software (http://www.graphpad.com/).
Graphs were obtained using SigmaPlot version 11.0.
3. Results and Discussion
In this study, we investigated the possible use of miR-34a in
the treatment of MM. We have previously investigated the
activity of miR-34a in different preclinical models using a
commercial available lipidic emulsion [28]. Moreover, we
previously developed SNALPs encapsulatingmiR-34a to treat
medulloblastoma cells in vitro [21]. Here we proposed the use
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Table 1: Mean diameter, polydispersity index, and zeta potential of the different SNALPs-based formulations.
Formulations miRNA chemistry Targeting ligand Mean diameter (nm) ± SD PI ± SD ZP (mV) ± SD
SNALP1 Wild type — 157.18 ± 17.18 0.16 ± 0.03 −13.52 ± 2.28
SNALP2 OMet — 127.75 ± 10.68 0.25 ± 0.03 −5.19 ± 5.38
Tf-SNALP1 Wild type Tf 158.32 ± 10.25 0.14 ± 0.05 −23.62 ± 1.54
Tf-SNALP2 OMet Tf 130.84 ± 8.41 0.21 ± 0.02 −18.13 ± 4.39
Table 2: miRNA encapsulation into the SNALPs.
Formulations Actual loading(𝜇g miRNA/mg lipids)
Encapsulation
efficiency (%)
SNALP1 160.0 ± 4.8 80 ± 3
SNALP2 196.5 ± 10.6 98 ± 5
Theoretical loading: 200 𝜇g miRNA/mg lipids.
of SNALPs encapsulating miR-34a to treat MM in vivo. We
also investigated the possibility to modify the previously
developed SNALPs in order to obtain enhanced antitumor
activity. To do this, as first strategy, we encapsulated a
chemically modified miRNA into the SNALPs. In particular,
OMet miR-34a was selected due to substantial degree of
nuclease resistance and high binding affinity with the target
[30]. A second strategy consisted of Tf conjugation with
SNALPs in order to enhance targeting and delivery to cancer
cells in vivo. In fact, SKMM-1 MM cells (used in our study)
expressed on their surface significantly high levels of the TfR
as demonstrated by the analysis of TfR expression performed
during FACS analysis (Figure 1). Interestingly, the expression
of the receptor increased in a time-dependentmanner during
the culture of SKMM-1 cells suggesting its role in the survival
of these cells. Moreover, MM cells are characterized by an
over-expression of the Tf receptor [33, 34]. On the basis of
these data and on the known high rate of internalization of
the TfR, we were prompted to develop SNALPs armed with
Tf for the treatment of MM.
In Table 1, the developed formulations, as well as their
characteristics in terms of mean diameter, PI, and ZP, are
reported. SNALPs have a mean diameter ranging between
about 128 and 158 nm; the use of an OMet miRNA slightly
decreasedmean diameter. All the formulations have a narrow
size distribution, although a slight increase from 0.16 to 0.25
was observed when encapsulating an OMet miR-34a.
In Table 2, the amount of miR-34a encapsulated into
the SNALPs is reported. All the formulations displayed a
high amount of miR-34a encapsulated into the SNALPs.
In particular, wild type miR-34a was encapsulated with an
efficiency of about 80%.This result was not surprising and in
agreement with other previously developed SNALPs formu-
lations [17, 21]. Interestingly, the use of an OMet miRNA led
to a significant increase of the encapsulation efficiency (about
98% of the miRNA initially used in the formulation). The
interaction between the negative charge of nucleic acid and
the positive one of cationic lipid is the driving force for the
encapsulation of nucleic acids into the SNALPs [17].However,
an OMet miR-34a, if compared to a wild type miR-34a, is
more lipophilic, due to the presence of the methyl residue
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Figure 1: FACS analysis of the surface expression of TfR in SKMM-
1 cells. SKMM-1 cells were cultured for 24, 48, and 72 h and the
expression of CD71 (TfR) was evaluated at FACS as reported in
Section 2. The intensity of TfR expression was represented as % of
mean fluorescence intensity (MFI) calculated by comparing theMFI
of cells incubatedwith antibodies with that of cells incubated in PBS.
A significant increase of MFI was observed in cells labelled with
anti-TfR (empty squares) if compared with that of cells labelled with
irrelevant IgG1 (full squares) suggesting a significant expression of
TfR on the surface of SKMM-1 cells. Each value was the mean of
at least three different determinations performed in three different
experiments. Bars, SEs.
bound to 2󸀠-position of the sugar moiety of each nucleotide.
Therefore, in our study, an additive hydrophobic interaction
between the miRNA and the lipid bilayer can represent an
additional contribution to high miRNA loading into the
SNALPs, when encapsulating a completely 2󸀠-O methylated
miRNA.
Thereafter, we modified the surface of SNALPs with Tf in
order to achieve an additional improvement of the delivery
in MM cells. SNALPs modified with targeting ligands have
previously been reported for glioblastoma cells [31]. In the
study from Costa et al., SNALPs were modified by postin-
sertion method. In the present work, we preferred to use a
different approach and Tf was coupled to preformed SNALPs.
Tf binding to the nanoparticle surface did not significantly
affect the size characteristics of the vesicles. On the contrary,
a slight decrease of the PI, from 0.16 to 0.14 and from
0.25 to 0.21, was observed for both SNALP1 and SNALP2,
respectively. This slight increase of PI can be explained with
the further purification step after the conjugation with Tf.
Tf-SNALPs also showed a significant decrease of the zeta
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Figure 2: Systemic delivery of miR-34a SNALPs formulations inhibits growth of human MM tumors in mice. (a) Mice carrying palpable
subcutaneous SKMM-1 tumor xenografts were treated with 20𝜇g of pre-miR-34a or miR-34a OMet SNALPs or Tf-SNALPs formulations
by intravenous tail vein injections. Caliper measurement of tumors was taken every 2 days from the day of first treatment. Averaged tumor
volumes of 5 mice per group are reported ± SD. (b) Survival curves (Kaplan-Meier) of treated mice show prolongation of survival after
formulated miR-34a treatment compared to controls (log-rank test, 𝑃 < 0.005). Survival was evaluated from the first day of treatment until
death or sacrifice.
potential (Table 1), as expected by the presence of the protein
on the vesicle surface. The Tf conjugation on the preformed
SNALPs did not affect miRNA encapsulation into the vesicles
(data not shown).
We next explored the effects of the systemic delivery
of miR-34a SNALPs formulations in controlling the growth
of SKMM-1 xenografts. When subcutaneous MM tumors
became palpable, mice were randomized and systemically
treated, via tail vein, with different miR-34a or miR-NC
SNALPs formulations at a concentration of 1mg miR-34a/kg
per mouse. Following 5 injections (3 days apart), a significant
antitumor effect of miR-34a SNALPs formulation (SNALP 1)
versus the control was detected (Figure 2(a)). The treatment
with plain SNALPs did not elicit any effect on the tumor
growth (Figure 2(a)).The use of SNALPs encapsulatingOMet
miR-34a resulted in a lower inhibition of tumor growth,
compared to SNALPs encapsulating wild type miR-34a. If we
consider that theONsmodificationwith a 2󸀠-O-methyl group
maintains a strong base-pairing with target [32], a different
delivery mechanism of the miRNA from the vesicle could
be responsible for the lower antitumor activity when using
SNALPs encapsulating OMet miR-34a. The modification of
Tf conjugation with SNALPs affected miRNA antitumor
activity, depending on the RNA chemistry. In particular,
the SNALPs conjugation with Tf significantly increased the
effect of OMet miR-34a on tumor growth (Figure 2(a)). In
particular, after 9 days from the beginning of the treatment,
the effect of Tf-SNALPs encapsulating OMet miR-34 was
comparable to that obtained in animal treated with SNALPs
encapsulating wild type miR-34a. Surprisingly, conjugation
with Tf had no effect on SNALPs encapsulating wild type
miR-34a. The increased efficacy of the treatment, observed
in the case of Tf-SNALP2, can be explained with a higher
interaction and uptake of SNALPs inMM cells, characterized
by an overexpression of TfR (see also Figure 1) [33, 34]. The
importance of the TfR for the development of malignant
human hematopoietic has been well established [35]. More-
over, in the case of metastasis originated by the MM cells, an
increased growth of vessel characterizes the tumor mass. It
has been demonstrated that SNALPs predominantly deliver
siRNA to areas adjacent to functional tumor blood vessels
[36]. Therefore, in our study, a targeting of tumor vessel,
characterized by an enhanced expression of the TfR, can
also be hypothesized. It is worthy of note that the use of
Tf was beneficial only in the case of SNALPs encapsulating
wild type miR-34a. To justify these findings, we hypothesize
that the animal treatment with SNALP1 led to the highest
miRNA delivery, in these experimental conditions. For this
reason, animal treatment with Tf-SNALP1 did not result in
an increased inhibition of the tumor growth; in line with
this hypothesis, the use of Tf-SNALP2 led to an increased
inhibition of the tumor growth, which was similar to that
obtained in animals treated with SNALP1 and Tf-SNALP1.
In Figure 2(b), themice survival following treatment with
the different SNALP-based formulations is reported. All the
animals treated with plain SNALPs died after 17 days of
treatment. Mice survival was prolonged with all the SNALP-
based formulations encapsulating miR-34a. In particular,
mice treatment with SNALPs containing wild type miR-34a
or OMet miR-34a resulted in mice survival until 28-29 days
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from the beginning of the treatment. The conjugation of Tf
with SNALPs containing wild type miR-34a did not prolong
mice survival. Surprisingly, the use of Tf-conjugated SNALPs
encapsulating OMet miR-34a resulted in a significant pro-
longation of the mice survival until 49 days. This could be
explained with the higher biological stability of OMet miR-
34a that can result in the highest persistence of the miR-34a
into the cells. Of course, the superiority of the formulation
Tf-SNALP2 was not observed in the experiments of tumor
growth, where the animals were sacrificed, accordingwith the
institutional guidelines, following 17 days from the beginning
of the treatment.
4. Conclusions
In this work, we developed SNALPs to deliver miR-34a.
SNALPs were also modified to enhance miR-34a delivery
in cancer. The two strategies used, the encapsulation of a
chemicallymodifiedOMetmiR-34a and the bindingTf on the
nanoparticle surface, did not affect the technological prop-
erties of the nanocarriers. The antitumor effect of miR-34a
was demonstrated in an experimental animal model of MM.
A significant inhibition of the tumor growth was observed
in animals treated with all the formulations. However, only
the combination of OMet miR-34a and Tf-conjugation with
SNALPs resulted in a significant prolongation of the mice
survival.
This study demonstrated that miR-34a represents a pow-
erful tool to treat tumors asMM, for which present treatment
can only prolong the survival. However, this kind of therapy
will need to develop ad hoc delivery systems in order to
optimize the anticancer activity of miRNAs. As shown in
this work, chemical modifications aimed to improve the
biological stability of the miRNA that could be successfully
combined with targeting approaches based upon the active
delivery of the nanotechnological devices. This approach can
be reasonably extended to deliver miRNA and other nucleic
acids in other tumors characterized by over-expression of
TfR. Additional studies are required to investigate if the
developed treatment can be associated to toxicity in healthy
tissue.
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